Clinical trial • Phase III • Oncology|Gastroenterology|Other
Clinical trial in Colorectal cancer with liver metastases|Metastatic colorectal cancer
Phase III trial for Colorectal cancer with liver metastases|Metastatic colorectal cancer. 45 participants.
Overview
- Trial Therapeutic Area
- Oncology|Gastroenterology|Other
- Trial Disease
- Colorectal cancer with liver metastases|Metastatic colorectal cancer
- Trial Stage
- Phase III
- Drug Modality
- Radiopharmaceutical|Diagnostic agent
Key dates
- Initial CTIS Submission Date
- 01-12-2023
- First CTIS Authorization Date
- 27-03-2024
Trial design
Phase III trial across 1 site in Netherlands.
- Target Sample Size
- 45
Recruitment
- Planned Sample Size
- 45
- Recruitment Window Months
- 89
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 45
Netherlands
- Earliest CTIS Part Ii Submission Date
- 15-03-2024
- Latest Decision Or Authorization Date
- 12-09-2025
- Processing Time Days
- 546
- Number Of Sites
- 1
- Number Of Participants
- 45
Sites
- Site Name
- Universitair Medisch Centrum Utrecht
- Department Name
- Nuclear Medicine
- Principal Investigator Name
- Marnix Lam
- Principal Investigator Email
- m.lam@umcutrecht.nl
- Contact Person Name
- Marnix Lam
- Contact Person Email
- m.lam@umcutrecht.nl
- Number Of Participants
- 45
Sponsor
Primary sponsor
- Full Name
- Universitair Medisch Centrum Utrecht
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Related trials
Other published trials that may interest you.
- Technetium (99mTc) galactosyl serum albumin for Hepatic tumor|Hepatic tumor(s)
- TISLELIZUMAB for Gastric adenocarcinoma|Gastroesophageal junction adenocarcinoma
- GALLIUM (68GA) CHLORIDE for Cholangiocarcinoma | Pancreatic carcinoma (including pancreatic ductal adenocarcinoma)
- PEMBROLIZUMAB for Metastatic colorectal cancer|Locally advanced or metastatic prostate cancer
- ARGIPRESSIN for Disseminated cancer